Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib in
EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC.